

## DAFTAR PUSTAKA

1. Sugihartono T, Maimunah U, Wibowo BP, et al. *Sirosis Hati : Translasi dari Ilmu Dasar ke Ilmu Terapan*. Airlangga University Press; 2025.
2. Liu Y Bin, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. *World J Gastroenterol* 2022;28(41):5910–30.
3. PPHI T. *PENATALAKSANAAN HIPERTENSI PORTAL*. Perhimpunan Peneliti Hati Indonesia (PPHI); 2021.
4. Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis — aetiology, trends and predictions. *Nat Rev Gastroenterol Hepatol* 2023;20(6):388–98.
5. WHO. *Liver cirrhosis (15+), age-standardized death rates by country*. 2016;
6. Chapman B, Sinclair M, Gow PJ, Testro AG. Malnutrition in cirrhosis: More food for thought. *World J Hepatol* 2020;12(11):883–96.
7. Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021;74(3):1611–44.
8. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019;48(4):601–601.
9. Rizka A, Dwimartutie N, Julia V, et al. *Konsensus Nasional Diagnosis, Pencegahan dan Tata Laksana Sarkopenia di Indonesia 2023*. 1st ed. Perkumpulan Informasi dan Penerbitan Interna (PIP Interna); 2023.
10. Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. *Metabolism* 2023;144(March):155533.
11. Dhaliwal A, Armstrong MJ. Sarcopenia in cirrhosis: A practical overview. *Clin Med J R Coll Physicians London* 2020;20(5):489–92.
12. Ponziani FR, Antonio G. Sarcopenia in Patients with Advanced Liver Disease. *Curr Protein Pept Sci* 2018;19(7):681–91.
13. Ali SH, Sneineh AA, Hasweh R. Nutritional assessment in patients with liver cirrhosis. *World J Hepatol* 2022;14(9):1694–703.
14. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J Am Med Dir Assoc* [Internet] 2020;21(3):300-307.e2. Available from: <https://doi.org/10.1016/j.jamda.2019.12.012>
15. Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. *J Gastroenterol* 2019;54(10):845–59.
16. Faron A, Abu-Omar J, Chang J, et al. Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients. *Front Med* 2022;9(April):1–11.
17. Kamimura H, Sato T, Natsui K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: A review of current knowledge. *Int J Mol Sci* 2021;22(3):1–16.
18. Xiao LY, Dai M, Zhao F, et al. Assessing the risk factors associated with sarcopenia in patients with liver cirrhosis: a case–control study. *Sci Rep* [Internet] 2023;13(1):1–10. Available from: <https://doi.org/10.1038/s41598-023-48955-z>
19. Kim S, Sohn JH, Lee JG, Jun DW, Kim Y. Presence of sarcopenia and its rate are independently associated with long-term mortality in patients with liver cirrhosis. *Korean Med Sci* 2018;33(50):1–13.
20. Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with liver cirrhosis: a meta-analysis. *J Hepatol* 2022;76(3):588–99.
21. Vitali A, Zurlo A, Volpato S. Vitamin D Deficiency and Sarcopenia in Older



- Persons. *J Am Med Dir Assoc* 2020;21(3):300–7.
22. Dzik KP, Kaczor JJ. Mechanisms of vitamin D on skeletal muscle function: oxidative stress, energy metabolism and anabolic state. *Eur J Appl Physiol* [Internet] 2019;119(4):825–39. Available from: <http://dx.doi.org/10.1007/s00421-019-04104-x>
  23. Saeki C, Kanai T, Nakano M, et al. Low serum 25-hydroxyvitamin D levels are related to frailty and sarcopenia in patients with chronic liver disease. *Nutrients* 2020;12(12):1–13.
  24. Warner ER, Satapathy SK. Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions. *J Clin Exp Hepatol* 2023;13(1):162–77.
  25. Murata K, Namisaki T, Fujimoto Y, et al. Clinical Significance of Serum Zinc Levels on the Development of Sarcopenia in Cirrhotic Patients. *Cancer Diagnosis Progn* 2022;2(2):184–93.
  26. Katayama K, Kawaguchi T, Shiraishi K, et al. The Prevalence and Implication of Zinc Deficiency in Patients With Chronic Liver Disease. *J Clin Med Res* 2018;10(5):437–44.
  27. EASL. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* [Internet] 2019;70:172–93. Available from: <https://doi.org/10.1016/j.jhep.2018.06.024>
  28. Coletta G, Phillips SM. An elusive consensus definition of sarcopenia impedes research and clinical treatment: A narrative review. *Ageing Res Rev* [Internet] 2023;86(February):101883. Available from: <https://doi.org/10.1016/j.arr.2023.101883>
  29. Setiati. *Buku Ajar Ilmu Penyakit Dalam*. 6th ed. Interna Publishing; 2024.
  30. Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and frailty in liver cirrhosis. *Life* 2021;11(5):1–13.
  31. AJ C-J, AA S. Sarcopenia. *Lancet* 2019;393:2636–46.
  32. Elsheikh M, El Sabagh A, Mohamed IB, Bhongade M, Jalal PK, Hassan MM. Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management. *World J Gastroenterol* 2023;29(46):6028–48.
  33. Lee JH, Cho AR, Lee YJ. Relationship between serum alkaline phosphatase and low muscle mass index among korean adults: A nationwide population-based study. *Biomolecules* 2021;11(6):0–8.
  34. Mazeaud S, Zupo R, Couret A, Panza F, Sardone R, Castellana F. Prevalence of Sarcopenia in Africa: A Systematic Review. *Clin Interv Aging* 2023;14:1021–35.
  35. Cui Y, Zhang M, Guo J, Jin J, Wang H, Wang X. Correlation between sarcopenia and cirrhosis: a meta-analysis. *Front Nutr* 2023;10(January):1–12.
  36. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. *J Hepatol* 2016;65(6):1232–44.
  37. Liguori I, Russo G, Aran L, et al. Sarcopenia: Assessment of disease burden and strategies to improve outcomes. *Clin Interv Aging* 2018;13:913–27.
  38. Topan MM, Sporea I, Dănilă M, et al. Impact of Sarcopenia on Survival and Clinical Outcomes in Patients With Liver Cirrhosis. *Front Nutr* 2021;8(October):1–6.
  39. Allen SL, Quinlan JJ, Dhaliwal A, et al. Sarcopenia in chronic liver disease: Mechanisms and countermeasures. *Am J Physiol - Gastrointest Liver Physiol* 2021;320(3):G241–57.
  40. Sinclair M. Controversies in diagnosing sarcopenia in cirrhosis—Moving from research to clinical practice. *Nutrients* 2019;11(10):1–16.



Velch N, Dasarathy S. REVIEW Synthesis Exercise and physical activity in opportunities or perils. *J Appl Physiol* 2020;128(6):1547–67.

Michitaka K, Izumoto H, et al. Relative changes in handgrip strength and muscle volume in patients with chronic liver disease over a 2-year observation. *Hepatol Res* 2018;48(7):502–8.

Hosoyama T, Tomida M, et al. Influence of vitamin D on sarcopenia

- pathophysiology: A longitudinal study in humans and basic research in knockout mice. *J Cachexia Sarcopenia Muscle* 2022;13(6):2961–73.
44. Widajanti N, Hadi U, Soelistijo SA, Syakdiah NH, Rosaudyn R, Putra HBP. The Effect of Vitamin D Supplementation to Parameter of Sarcopenia in Elderly People: a Systematic Review and Meta-Analysis. *Can Geriatr J* 2024;24(1):63–75.
  45. Saeki C, Kanai T, Ueda K, et al. Prognostic significance of sarcopenia and severe vitamin D deficiency in patients with cirrhosis. *JGH Open* 2023;7(5):351–7.
  46. Santangeli E, Abbati C, Chen R, et al. Pathophysiological-Based Nutritional Interventions in Cirrhotic Patients with Sarcopenic Obesity: A State-of-the-Art Narrative Review. *Nutrients* 2024;16(3).
  47. Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. *J Hepatol* 2021;75:S147–62.
  48. Tsai CC, Wang PC, Hsiung T, et al. Sarcopenia in Chronic Kidney Disease: A Narrative Review from Pathophysiology to Therapeutic Approaches. *Biomedicines* 2025;13(2):1–18.
  49. Sulaiman A, Akbar N, Lesmana LA, Noer S, editors. *Buku Ajar Ilmu Penyakit Hati*. First Edit. 2007.
  50. Zhou L, Fu J, Ding Z, Jin K, Wu R, Ye LX. Comparison of GLIM, SGA, PG-SGA, and PNI in diagnosing malnutrition among hepatobiliary-pancreatic surgery patients. *Front Nutr* 2023;10.
  51. Borhofen SM, Gerner C, Lehmann J, et al. The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. *Dig Dis Sci* :1735–1743.
  52. Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum Albumin Levels and Inflammation. *Int J Biol Macromol* 2021;(184):857–62.
  53. Gani LU, How CH. Vitamin D deficiency. *Singapore Med J* 2015;56(8):433–7.
  54. Hennigar SR, Lieberman HR, Fulgoni VL, McClung JP. Serum zinc concentrations in the US population are related to sex, age, and time of blood draw but not dietary or supplemental zinc. *J Nutr* 2018;148(8):1341–51.
  55. KDIGO Executive Committee K. *KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. 2024.
  56. Heidenreich PA, Bozkurt B, Aguilar D, et al. *2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines*. 2022.
  57. National Cancer Institute N. *What Is Cancer?* [Internet]. *Natl. Cancer Inst.* 2021 [cited 2025 Jun 7]; Available from: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer>
  58. *Perkumpulan Gastroenterologi Indonesia P. Inflammatory bowel disease (ibd)*. 1st ed. Jakarta Pusat: *Perkumpulam Gastrointestinal Indonesia*; 2019.
  59. Warner ER, Aloor FZ, Satapathy SK. A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient. *Transl Gastroenterol Hepatol* 2022;7(I):1–11.
  60. Tuo S, Yeo YH, Chang R, et al. Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. *Clin Nutr* 2023;42(1):84–94.
  61. Jorgurevic I, Mamic B, et al. Detection of Sarcopenia in Patients with Liver Cirrhosis Using the Bioelectrical Impedance Analysis. *Nutrients* 2023;15(15):1–15.
  62. Zhao YP, Zhao Y, Deng SL, Yu K. Regulation of Myostatin on the Growth and Development of Skeletal Muscle. *Front Cell Dev Biol* 2021;9(December):1–10.



63. Evuri P, Selvi C, E M, et al. Study of Prevalence of Sarcopenia in Chronic Liver Disease and its Impact on Outcomes. *Int J Innov Res Med Sci* 2022;7(07):335–9.
64. Ohashi K, Ishikawa T, Hoshi A, et al. Relationship Between Sarcopenia and Both Physical Activity and Lifestyle in Patients With Chronic Liver Disease. *J Clin Med Res* 2018;10(12):920–7.
65. Saeki C, Tsubota A. Influencing factors and molecular pathogenesis of sarcopenia and osteosarcopenia in chronic liver disease. *Life* 2021;11(9).
66. Wang J, Liu C, Zhang L, et al. Prevalence and associated factors of possible sarcopenia and sarcopenia: findings from a Chinese community-dwelling old adults cross-sectional study. *BMC Geriatr* 2022;22(1):1–10.
67. Feng H, Wang X, Mao L, et al. Relationship between sarcopenia/ myosteatosis and frailty in hospitalized patients with cirrhosis: a sex-stratified analysis. *Ther Adv Vaccines* 2021;12:1–12.
68. Filip PV, Cuciureanu D, Pop CS, Marinescu AN, Furtunescu F, Diaconu LS. Frailty and Sarcopenia Assessment in Patients with Advanced Chronic Liver Disease in a Tertiary Center in Romania. *Diagnostics* 2025;15(1):1–13.
69. Gowda C, Compher C, Valerianna K, Amorosa V. Association between chronic hepatitis C virus infection and low muscle mass in U.S. adults. *J Viral Hepatol* 2014;21(12):938–43.
70. Li L, Fu X, He N, Gan W, Zhao Y, Xie R hua. Association of frailty with activity levels and sedentary behaviours in patients with hepatitis B cirrhosis: A cross-sectional study. *Nurs Open* 2024;11(1):1–7.
71. Liao C-D, Chen H-C, Tsao J-Y, Huang S-W, Liou T-H. Effects of Muscle Strength Training on Muscle Mass Gain and Hypertrophy in Older Adults With Osteoarthritis : A Systematic Review and Meta Analysis. *Am Coll Rheumatol* 2020;72(12):1703–18.
72. Richter EA. Is GLUT4 translocation the answer to exercise-stimulated muscle glucose uptake? *Am J Physiol - Endocrinol Metab* 2021;320(2):E240–3.
73. Suzuki M, Ishikawa T, Ohashi K, et al. Serum zinc concentration as a potential predictor of presarcopenia in patients with chronic liver disease: a preliminary study. *Transl Gastroenterol Hepatol* 2024;9:0–2.
74. Hanai T, Nishimura K, Unome S, et al. Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis. *J Gastroenterol* [Internet] 2024;59(10):932–40. Available from: <https://doi.org/10.1007/s00535-024-02137-4>
75. Cederholm T, Bosaeus I, Barazzoni R, et al. Diagnostic criteria for malnutrition - An ESPEN Consensus Statement. *Clin Nutr* 2015;34(3):335–40.
76. Topan MM, Sporea I, Dănilă M, et al. Comparison of Different Nutritional Assessment Tools in Detecting Malnutrition and Sarcopenia among Cirrhotic Patients. *Diagnostics* 2022;12(4).
77. Zhang P, Wang Q, Zhu M, Li P, Wang Y. Differences in nutritional risk assessment between NRS2002, RFH-NPT and LDUST in cirrhotic patients. *Sci Rep* [Internet] 2023;13(1):1–8. Available from: <https://doi.org/10.1038/s41598-023-30031-1>
78. Thyloor Kenchappa S, Sharma S, Kumar M, Ghuman SS, Arora A, Ranjan P. A Prospective Study of Prevalence and Impact of Sarcopenia on Short-term Mortality in Hospitalized Patients with Liver Cirrhosis. *J Clin Exp Hepatol* [Internet] 2023;13(5):946–54. Available from: <https://doi.org/10.1016/j.jceh.2023.05.001>
79. Santos M, Nicola MRC, Bezerra NTC, Sardinha JCG, Sampaio de Souza Morais AP. Genital ulcers caused by sexually transmitted agents. *An Bras Dermatol* 2021;96(1):551–65.
80. Rojas JR, Rojas-huayta VM, Aparco- JP, Paulo S, Pablo J. Sarcopenia y albúmina en pacientes con enfermedad hepática crónica: una revisión sistemática con metaanálisis. 2021;590–603.



81. Grüngreiff K, Gottstein T, Reinhold D, Blindauer CA. Albumin substitution in decompensated liver cirrhosis: Don't forget zinc. *Nutrients* 2021;13(11).
82. Van Ancum JM, Tuttle CSL, Koopman R, et al. Albumin and C-reactive protein relate to functional and body composition parameters in patients admitted to geriatric rehabilitation after acute hospitalization: findings from the RESORT cohort. *Eur Geriatr Med* [Internet] 2022;13(3):623–32. Available from: <https://doi.org/10.1007/s41999-022-00625-5>
83. Nishikawa H, Enomoto H, Yoh K, et al. Serum zinc concentration and sarcopenia: A close linkage in chronic liver diseases. *J Clin Med* 2019;8(3):5–9.
84. Hernández-Camacho JD, Vicente-García C, Parsons DS, Navas-Enamorado I. Zinc at the crossroads of exercise and proteostasis. *Redox Biol* [Internet] 2020;35(January):101529. Available from: <https://doi.org/10.1016/j.redox.2020.101529>
85. Ullah MI, Alameen AAM, Al-Oanzi ZH, et al. Biological Role of Zinc in Liver Cirrhosis: An Updated Review. *Biomedicines* 2023;11(4).
86. Okubo T, Atsukawa M, Tsubota A, et al. Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease. *PLoS One* [Internet] 2024;19(3 March):1–14. Available from: <http://dx.doi.org/10.1371/journal.pone.0299313>
87. Chakravarthy M V., Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. *Endocrinol Diabetes Metab* 2020;3(4):1–13.
88. Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. *Front Nutr* 2022;8(January):1–17.
89. Han Na J, Chang Hee J, You-Cheol H. Sarcopenia in youth. *Metab* 144, 155557 2023;

